Loading stock…

10x Genomics, Inc. (TXG) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

10x Genomics, Inc.

TXGMarket cap $10BPrice $77.3

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Makes gene-sequencing and imaging tools that let scientists see which genes activate in individual cells, not just tissue averages. Its Chromium and Xenium platforms are reshaping how researchers map diseases like cancer at single-cell resolution.

In Bastion Portfolios?

52W Return+553%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+8%6

Revenue Forecast

Rev CAGR (1y)-4%2

Rev CAGR (3y)+5%4

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+12%7

EPS Growth Y+3+232%10

Quality

Margins

EBIT Margin-13%1

Net Income Margin-12%1

Free Cash Flow Margin20%8

Debt

Net Debt/EBITDAna–

Efficiency

ROE-9%1

ROA-7%1

Earnings Stability22

GEAR+VERY WEAK4

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)2001

P/BV12.21

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield1.2%3

Dividend Yieldna–

Momentum

Short term

1 month return+15%10

3 month return+79%10

YTD return+374%10

Mid term

Price vs 52wHigh75%4

1 year return+560%10

Long term

3 year return+98%7

5 year return-50%1

Risk Shield

Price Risk

Beta1.52

Volatility74%1

Free Cash Flow

Free Cash Flow Margin20%8

Free Cash Flow Yield1.2%3

Quality

ROCE-9%1

Earnings Stability22

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

TXG10x Genomics

Revenue FY25$643M

GROWTH RATING↗

AVERAGE42 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+12%7

EPS growth, FY28E+232%10

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

A mid-pack grower, ahead of 42% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 8%/yr over the last 3 years and is set to keep growing around 5%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG74 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+15%10

3-month return+79%10

YTD return+374%10

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+560%10

3-year return+98%7

5-year return-50%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 560% over the past year, but 25% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+15%), over three months (+79%) and so far this year (+374%).

WATCH

Average long-term results. Multi-year returns are middling (+98% over three years and -50% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on 10x Genomics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TXG10x Genomics

Revenue FY25$643M

GROWTH RATING↗

AVERAGE42 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+12%7

EPS growth, FY28E+232%10

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

A mid-pack grower, ahead of 42% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 8%/yr over the last 3 years and is set to keep growing around 5%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG74 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+15%10

3-month return+79%10

YTD return+374%10

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+560%10

3-year return+98%7

5-year return-50%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 560% over the past year, but 25% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+15%), over three months (+79%) and so far this year (+374%).

WATCH

Average long-term results. Multi-year returns are middling (+98% over three years and -50% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on 10x Genomics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community